ArticleScience advances2023
Mapping the genomic landscape of multidrug resistance in
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Identification of genetic markers of quinine partial resistance in Plasmodium falciparum.Nature microbiology · 2026Article
- A Multidimensional Analysis of the Bimodal Piperaquine Response inbioRxiv : the preprint server for biology · 2026Article
- Slowing the spread of treatment failure to artemisinin-based combination therapies in Uganda.Nature communications · 2026Article
- AbioRxiv : the preprint server for biology · 2026Article
- Functional assessment of prevalentmBio · 2026Article
- NovelmBio · 2026Article
- Collateral hypersensitivity between ZY19489 and piperaquine neutralizes PfCRT-mediated drug efflux and Plasmodium falciparum resistance.Nature communications · 2026Article
- No evidence of molecular markers of piperaquine resistance in southeastern Nigeria.Malaria journal · 2025Article
- Cryptosporidium parvum multidrug resistance protein confers resistance to toxic gut microbial metabolite.Cell host & microbe · 2025Article
- The plasmepsin-piperaquine paradox persists in Plasmodium falciparum.PLoS pathogens · 2025Article
- Plasmodium falciparum African PfCRT Mutant Isoforms Conducive to Piperaquine Resistance Are Infrequent and Impart a Major Fitness Cost.The Journal of infectious diseases · 2025Article
- SKSR1 identified as key virulence factor in Cryptosporidium by genetic crossing.Nature communications · 2025Article
- Genetic surveillance of Plasmodium falciparum populations following treatment policy revisions in the Greater Mekong Subregion.Nature communications · 2025Article
- The spread of molecular markers of artemisinin partial resistance and diagnostic evasion in Eritrea: a retrospective molecular epidemiology study.The Lancet. Microbe · 2025Article
- Genomic analysis of global Plasmodium vivax populations reveals insights into the evolution of drug resistance.Nature communications · 2024Article
- Genome sequencing of Plasmodium malariae identifies continental segregation and mutations associated with reduced pyrimethamine susceptibility.Nature communications · 2024Article
- Artemisinin-resistant malaria.Clinical microbiology reviews · 2024Review
- Population genomics and transcriptomics of Plasmodium falciparum in Cambodia and Vietnam uncover key components of the artemisinin resistance genetic background.Nature communications · 2024Article
- Dihydroartemisinin-Piperaquine Combination in the Treatment of UncomplicatedJournal of clinical medicine · 2024Review
- Emerging threat of artemisinin partial resistance markers (pfk13 mutations) in Plasmodium falciparum parasite populations in multiple geographical locations in high transmission regions of Uganda.Malaria journal · 2024Article
Corrections and comments
- Update of
Authors and funding
24 authors at 4 institutions in 2 countries.
Sachel MokDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-9605-0154
Tomas YeoDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-2923-6060
Davin HongDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0009-0007-7363-9752
Melanie J ShearsDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0002-8226-4354
Leila S RossDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-4360-5213
Kurt E WardDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-3614-436X
Satish K DhingraDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Mariko KanaiDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-7767-2046
Jessica L BridgfordDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-8381-1121
Abhai K TripathiDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0001-9848-0142
Godfree MlamboDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0001-8917-9710
Anna Y BurkhardDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Megan R AnsbroLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0002-7131-1610
Kate J FairhurstDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Eva Gil-IturbeDepartment of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-4046-5756
Heekuk ParkDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-5815-9717
Felix D RozenbergDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-5532-9773
Jonathan KimDepartment of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-2594-3251
Filippo ManciaDepartment of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-3293-2200
Rick M FairhurstLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Matthias QuickDepartment of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-8620-827X
Anne-Catrin UhlemannCenter for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-9798-4768
Photini SinnisDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0003-2954-7547
David A FidockDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-6753-8938
Columbia University Irving Medical Center · USJohns Hopkins University · USNational Institutes of Health · USNanyang Technological University · SG
Funding
Role of pfcrt in chloroquine resistance in P. falciparumR01AI050234 · NIAID · YESHIVA UNIVERSITY · PI FIDOCK, DAVID A · 2001 to 2015
$5.7MLeveraging PfCRT Structure to Discern Function and Predict Emergence of Drug-Resistant MalariaR01AI147628 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock, Filippo Mancia · 2019 to 2026
$5.1MDefining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug ResistanceR37AI050234 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2018 to 2026
$4.4MDefining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4MElucidating the molecular basis of piperaquine resistance in Plasmodium falciparumR01AI124678 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2016 to 2026
$4.3MThe Skin Phase of Malaria Infection (Sharon Patray Diversity Supplement)R01AI132359 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SINNIS, PHOTINI · 2017 to 2021
$2.7MDeciphering the role of Plasmodium falciparum plasmepsin 2/3 amplifications in mutant pfcrt-driven piperaquine resistanceR21AI159558 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2021 to 2022
$446kNIAID NIH HHS R01 AI050234NIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI124678NIAID NIH HHS R01 AI132359NIAID NIH HHS R01 AI147628NIAID NIH HHS R21 AI159558NIAID NIH HHS R37 AI050234
Abstract
Drug-resistant
Indexed as
Malaria, FalciparumParasitesAnimalsArtemisininsDrug ResistanceDrug Resistance, MultipleGenomicsMicePlasmodium falciparumartemisininArtemisinins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.